Of 20 patients with Ph+ CP CML evaluated for new BCR-ABL1 point mutations, one patient in the third-line cohort with a baseline Y253F mutation had a newly detectable T315I mutation. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.